Table 3.
Study results
| Lipiodol (± SD) | Lipiodol + DSM (± SD) | Overall (± SD) | p-value | |
|---|---|---|---|---|
| Tumor volume | ||||
| Absolute (cm3) | − 1.40 (± 88.46) | − 3.46 (± 190.60) | − 2.76 (± 151.60) | 0.653 |
| Relative (%) | − 21.45 (± 64.36) | − 22.95 (± 61.39) | − 21.45 (± 62.34) | 0.556 |
| Diameter | ||||
| Absolute (cm) | − 2.64 (± 15.89) | − 1.63 (± 7.09) | − 1.97 (± 12.08) | 0.562 |
| Relative (%) | − 11.86 (± 24.53) | − 4.06 (± 21.01) | − 6.26 (± 22.57) | 0.678 |
| mRECIST | 0.010 | |||
| Complete response | 0 | 3 | 3 | |
| Partial response | 2 | 7 | 9 | |
| Stable disease | 21 | 17 | 38 | |
| Progressive disease | 3 | 1 | 4 | |
| Necrotic area | ||||
| Absolute (cm) | − 0.88 (± 6.83) | 1.10 (± 6.15) | 0.98 (± 6.43) | 0.222 |
| Relative (%) | − 4.57 (± 42.77) | 4.27 (± 38.65) | 0.01 (± 40.54) | 0.107 |
| Complications | 0.103 | |||
| Grade 1 | 6 | 5 | 11 | |
| Grade 2 | 1 | 1 | 2 | |
| ≥ Grade 3 | 0 | 0 | 0 | |
Bold values indicates significance
DSM degradable starch microspheres, mRECIST modified response evaluation criteria in solid tumors, SD standard deviation